Concepedia

Author

Vivien N. Jacobs

AstraZeneca (United Kingdom)

Also Known As

V Jacobs, V N Jacobs, V. Jacobs, VIVIEN N. JACOBS, Vivien Jacobs, Vivien N Jacobs, Vivien N. Jacobs

64

Publications

2.9K

Citations

14

H-Index

31

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)University of ManchesterAstraZeneca (Singapore)Vanderbilt University
VN

About

Vivien N. Jacobs is an author at AstraZeneca (United Kingdom) specializing in medicine, tumor biology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

257

2

Cell Biology

4

4

139

3

Health Sciences

1

1

19

4

Biochemistry

1

1

23

5

Immunology

1

1

86

Vivien N. Jacobs

×

15

Publications

2.9K

Citations

14

H-Index

YearCitations

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu,

Cancer Discovery

2014

2.2K

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Tim P. Green, Mike Fennell, Robin Whittaker,

Molecular Oncology

2009

254

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo

Catherine A. Eberlein, Jane Kendrew, Karen McDaid,

Oncogene

2012

86

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>

Sarah A. Loddick, Sarah J. Ross, Andrew Thomason,

Molecular Cancer Therapeutics

2013

77

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Barry R. Davies, Nin Guan, Armelle Logié,

Molecular Cancer Therapeutics

2015

70

Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells.

T. J. Franklin, Vivien N. Jacobs, Geraint Jones,

PubMed

1996

54

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

Nicolas Floc’h, Susan Ashton, Paula Taylor,

Molecular Cancer Therapeutics

2017

35

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial

Kenneth S. Thress, Vivien N. Jacobs, Helen K. Angell,

Journal of Thoracic Oncology

2017

24

Human colorectal carcinoma cells in vitro as a means to assess the metabolism of analogs of mycophenolic acid.

T. J. Franklin, Vivien N. Jacobs, Geraint Jones,

PubMed

1997

23

Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.

Darren A.E. Cross, Sue Ashton, Caroline A. Nebhan,

Molecular Cancer Therapeutics

2013

19

Page 1